Study guide
7.3 PET Radiopharmaceuticals
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
7.3 PET Radiopharmaceuticals
Key Takeaways Explain This Topic AI
F-18 (t½ ≈ 110 min, 511 keV annihilation photons) labels FDG, NaF, amyloid agents, fluciclovine, PSMA ligands, and other PET tracers; patient glucose control is critical for FDG
F-18 FDG is a glucose analog trapped after hexokinase phosphorylation—oncology, infection/inflammation, and myocardial viability are core indications
Somatostatin-receptor PET uses Ga-68 DOTATATE (Netspot®)/DOTATOC (t½ Ga-68 ≈ 68 min) or Cu-64 DOTATATE; PSMA PET uses F-18 piflufolastat (Pylarify®) or Ga-68 PSMA products (Illuccix®/Locametz®)
Cardiac PET perfusion commonly uses generator-produced Rb-82 (t½ ≈ 76 s) or cyclotron N-13 ammonia (t½ ≈ 10 min)
Prep traps: non-fasting/hyperglycemia for FDG, confusing amyloid vs tau agents, and mixing diagnostic PSMA/fluciclovine indications with wrong cancer pathways
Last updated: August 2026
7.3 PET Radiopharmaceuticals
Quick Answer: F-18 FDG (110 min) → glucose analog for oncology / infection / viability (NPO + glucose control). F-18 NaF → bone PET. Amyloid F-18 agents → brain plaques. Axumin® / PSMA agents → prostate pathways. Ga-68/Cu-64 DOTA-peptides → NETs. Rb-82 / N-13 ammonia → cardiac PET perfusion. All PET coincidence imaging uses 511 keV annihilation photons.
PET radiopharmaceuticals pair a positron emitter with a targeting molecule. After positron annihilation, detectors record 511 keV photon pairs. Entry-level CNMT focus: which tracer for which biology , half-life logistics, and prep traps—not full neurology research catalogs.
F-18 Family Physics Anchor
- Nuclide Approx. half-life Production note
- F-18 ~110 minutes Cyclotron
- Ga-68 ~68 minutes Usually Ge-68/Ga-68 generator
- Cu-64 ~12.7 hours Cyclotron
- Rb-82 ~76 seconds Sr-82/Rb-82 generator at bedside
- N-13 ~10 minutes On-site cyclotron (ammonia)
- C-11 ~20 minutes On-site cyclotron (less common in many clinics)
- F-18 FDG (Fluorodeoxyglucose)
- Mechanism
FDG is a glucose analog . It enters cells via GLUT transporters and is phosphorylated by hexokinase to FDG-6-phosphate, which is not significantly metabolized further along glycolysis—so it is metabolically trapped . Tissues with high glucose use (many malignancies, brain, heart under some conditions, activated inflammatory cells) accumulate FDG.
Indications
Domain Examples
Oncology Staging, restaging, treatment response for numerous FDG-avid cancers; unknown primary; solitary pulmonary nodule characterization (context-dependent)
Infection / inflammation FUO, selected osteomyelitis/spine infection, sarcoid, device infection workups (protocol-driven)
- Cardiology Myocardial viability (often with glucose-loading protocols distinct from oncology fasting)
- Neurology Selected epilepsy and dementia metabolic patterns
- Patient Prep (Oncology-Style Teaching)
- Prep element Why
- NPO ~4–6 hours (water OK per protocol) Lowers insulin and competitive glucose
Serum glucose check before injection Hyperglycemia reduces tumor contrast; many labs reschedule if glucose too high (thresholds protocol-specific, often roughly >150–200 mg/dL concern zone)
- Avoid strenuous exercise 24 h Prevents muscle uptake
- Warm, quiet uptake (~60 min) Reduces brown fat and muscle artifact
- Controlled diabetes management Coordinate insulin timing with the authorized user/protocol
- Pregnancy screening / breastfeeding policies Standard PET radiation counseling
Typical adult activity: often ~10–20 mCi (370–740 MBq) IV, weight-based in many labs. Image roughly 60 minutes after injection (protocols vary).
Traps: eating before FDG; insulin given immediately before injection driving muscle uptake; brown fat in cold patients; interpreting infection vs tumor without history; using oncology fasting rules unchanged for viability protocols.
F-18 Sodium Fluoride (NaF)
Mechanism: Bone mineral incorporation (fluoride ion exchanges onto hydroxyapatite)—high sensitivity PET bone imaging for osteoblastic metastases and selected bone viability questions.
- Item Teaching point
- vs Tc-99m MDP Higher sensitivity/resolution PET; different logistics/cost
- Admin IV; image often ~30–60+ min after injection
- Prep Hydrate; void; less “glucose drama” than FDG
- F-18 Amyloid Imaging Agents
These bind β-amyloid plaques in brain for Alzheimer disease workup support (positive/negative amyloid status)—not a stand-alone clinical diagnosis.
- Agent (brand) Notes
- Florbetapir (Amyvid®) F-18 amyloid PET
- Florbetaben (Neuraceq®) F-18 amyloid PET
- Flutemetamol (Vizamyl®) F-18 amyloid PET; often color-scale display teaching
Prep: minimize head motion; follow product-specific uptake times (often ~30–90 min class). Trap: amyloid-positive ≠ automatic Alzheimer diagnosis; correlation with neurology is mandatory. Distinguish from tau imaging ( flortaucipir , Tauvid®)—different target (neurofibrillary tau pathology overview-level only).
Prostate-Pathway PET: Fluciclovine and PSMA
Agent Mechanism (exam level) Flagship use
F-18 fluciclovine (Axumin®) Synthetic amino acid analog transported into prostate cancer cells Biochemically recurrent prostate cancer localization
F-18 piflufolastat (Pylarify®) PSMA -targeted ligand PSMA-positive prostate cancer imaging (staging/recurrence per labeling)
Ga-68 PSMA-11 (Illuccix®, Locametz®) PSMA binder (Ga-68) Similar PSMA PET indications; generator logistics
Axumin prep traps: short uptake time (often image ~3–5 min after injection begins for early frames—follow insert); avoid exercise; bladder activity management. PSMA traps: salivary/lacrimal/kidney/bladder physiologic uptake; recent ADT effects are interpretation nuances—know physiologic hot spots so you do not call them all metastases.
Somatostatin-Receptor PET
- Agent Nuclide half-life Role
- Ga-68 DOTATATE (Netspot®) Ga-68 ~68 min SSTR PET for NETs—successor mindset to Octreoscan
- Ga-68 DOTATOC Same Ga-68 Related SSTR peptide (availability varies)
- Cu-64 DOTATATE Cu-64 ~12.7 h SSTR PET with longer half-life logistics
Mechanism: peptides bind somatostatin receptors (especially subtype 2) on many neuroendocrine tumors. Hold/timing of cold somatostatin analog therapy matters (short-acting vs long-acting depot schedules). Compared with In-111 pentetreotide SPECT, PET offers higher resolution and quantitative SUVs.
Cardiac PET Perfusion Agents
- Agent Half-life Source Teaching use
- Rb-82 chloride ~76 seconds Sr-82/Rb-82 generator Rest/stress MPI PET; potassium-analog extraction
- N-13 ammonia ~10 minutes Cyclotron MPI PET; high extraction fraction
Ultra-short half-lives demand on-site production/infusion systems , precise timing, and generator QC (Rb-82 breakthrough limits for Sr-82/Sr-85). Pharmacologic stress is common. These are not FDG viability protocols—different biology and prep.
Other F-18 Agents (Overview)
- Agent Target idea Clinical niche
- F-18 fluoroestradiol (FES, Cerianna®) Estrogen receptor ER-positive breast cancer characterization
- F-18 flortaucipir (Tauvid®) Tau protein Tau PET in cognitive impairment workups (overview)
Know they exist and what they target; deep scoring criteria are specialist-level.
Master Selection Table
- Clinical goal Prefer
- Most oncology metabolic staging F-18 FDG
- Bone mets with PET sensitivity F-18 NaF
- Brain amyloid status Florbetapir / florbetaben / flutemetamol
- Prostate biochemical recurrence (amino acid) F-18 fluciclovine
- PSMA-avid prostate disease F-18 or Ga-68 PSMA agents
- SSTR-positive NETs Ga-68 DOTATATE/DOTATOC or Cu-64 DOTATATE
- Cardiac PET perfusion Rb-82 or N-13 ammonia
- Cardiac viability metabolism F-18 FDG (viability prep)
FDG + cookies before injection → ruined scan. Ga-68 DOTATATE → NETs, not PSMA. 76-second Rb-82 → generator at the scanner, not a 2-hour shipping isotope.